Background: Weight gain is an ongoing challenge when initiating insulin therapy in patients with type 2 diabetes mellitus (T2DM). However, if prediction of insulin-associated weight gain was possible on an individual level, targeted initiatives could be implemented to reduce weight gain. The aim of the present study was to identify predictors of weight gain in insulin-treated patients with T2DM. Methods: In all, 412 individuals with T2DM were, in addition to metformin or placebo, randomized into 18-month treatment groups with three different insulin analog treatment regimens (biphasic, aspart, detemir). Participants with excessive weight gain were defined as the group with weight gain in the 4th quartile (>6.2 kg).We developed a pattern classification method to predict individuals prone to excessive weight gain. Results: Over the 18-month treatment period, median weight gain among all 412 patients was 2.4 kg (95% prediction interval [PI] -5.6, 12.4 kg), whereas median weight gain for those in the upper 4th quartile (n = 103) was 8.9 kg (95% PI 6.3, 15.2 kg). No clinical baseline data were strong predictors of excessive weight gain. However, the weight gain during the first 3 months of the trial and the subsequent dose of insulin yielded a useful predictor for weight gain at the 18-month follow-up. Combining these two predictors into a prediction model with other clinical available information produced a receiver operating characteristic area under the curve of 0.80. Conclusions: We have developed a prediction model that could help identify a substantial proportion of individuals with T2DM prone to large weight gain during insulin therapy.
Introduction
At diagnosis, most individuals with type 2 diabetes mellitus (T2DM) are obese, experience postprandial blood glucose excursions, and have a sedentary lifestyle. 1, 2 Metformin is recommended by the American Diabetes Association (ADA) as a first-line diabetes drug to reduce blood glucose in order to achieve a target of HbA1c <53.0 mmol/mol (7.0%), but is not always sufficient. 3 In many individuals, it will eventually be necessary to initiate insulin treatment to achieve the target glycemic goal.
Along with improving glycemic control, weight gain is a frequent challenge in insulin treatment. 4 In the UKPDS (UK Prospective Diabetes Study), individuals with T2DM assigned to the intensive group had an average weight gain approximately 4 kg more (range 3.1-4.9; P < 0.0001) than the standard treatment arm. 5 Insulinassociated weight gain is problematic for several reasons. First, for every kilogram gained, the risk of coronary heart disease increases, along with adverse changes in the patient's lipid profile and blood pressure. [6] [7] [8] [9] In addition, when insulin treatment is postponed because of the patient's fear of gaining weight, this can negatively affect the patient's cardiovascular risk profile and increase morbidity and mortality. 10, 11 This psychological barrier associated with insulin treatment and the accompanying weight gain can affect compliance and diabetic control. Woman especially have been reported to omit or misuse insulin to manipulate their weight. 10 Weight gain with insulin therapy can be reduced, and being aware of the problem may help avoid weight gain. 10, 12 Lifestyle interventions, such as exercise and diet programs, have the potential to counteract insulin-induced weight gain. 13 Moreover, the type of insulin and form of therapy, as well as surgery and weight loss agents, could be options to prevent excessive weight gain. 13 Few studies have tried to identify risk factors predicting excessive weight gain during insulin treatment among patients with T2DM. van Dieren et al.
14 tried to determine the baseline characteristics and glucoselowering therapies associated with weight changes in patients from the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) trial and found that weight gain was associated with younger age, Caucasian ethnicity, smoking, and higher HbA1c.
If prediction of excessive weight gain was possible on an individual level, targeted initiatives could be undertaken in order to avoid or reduce the undesired insulinassociated weight gain. Previously, it was shown how simple techniques from machine learning could be successfully used in similar medical challenges within diabetes. 2, [15] [16] [17] In the present study, we investigated to what extent it is possible to predict individuals who will experience excessive weight gain during insulin treatment.
Methods
The present study used available clinical data at baseline and at the 3-month control visit from The Copenhagen Insulin and Metformin Therapy (CIMT) trial. 18 Our aim was to investigate whether this information could help identify individuals with T2DM who would experience excessive weight gain during insulin treatment.
Data collection
The primary objective of the CIMT trial was to evaluate the effect of an 18-month treatment with metformin versus placebo in combination with one of three insulin analog regimens. The primary results of the CIMT trial have been described elsewhere. 19, 20 In all, 412 participants with T2DM aged >30 years were randomly assigned to metformin or placebo in combination with one of the following insulin regimens: (i) biphasic insulin aspart 30 before dinner with a possible increase to two or three daily injections; (ii) insulin aspart before the main meals (three times daily) and insulin detemir before bedtime; or (iii) insulin detemir once daily before bedtime with a possible increase to two daily injections.
Weight, medical history, and blood samples were assessed at baseline. Every 3 months during the 18-month trial, participants were examined and weight and blood samples collected. Table 1 summarizes patient characteristics and data.
All participants provided written informed consent before taking part in the study. The study protocol was approved by the regional ethics committee (Region of Copenhagen Journal no. H-D-2007-112) and the Danish Medicines Agency (Journal no. 2612-3648) and was conducted in accordance with The Helsinki Declaration and guidelines for Good Clinical Practice (http://www.wma. net/en/30publications/10policies/b3/, accessed 23 May 2016). Overall, the volume of missing data used in the present substudy was low (<3%) and was handled using multiple imputation. 21 The aim of the present study was not to assess the arms; in the present study, patients from each arm were pooled together.
Prediction model
We developed a pattern classification method to predict individual weight gain into one of two classes: small weight gain or weight loss (corresponding to the 1st-3rd quartiles; <6.2 kg) or excessive weight gain (corresponding to the 4th quartile; ≥6.2 kg) during the 18-month trial.
Logistic regression classification was chosen for the basis of the model because of the possibility of including both nominal and ordinal data types. Moreover, logistic regression has a transparent decision model, which makes it appealing in a clinical setting as a decision support system. We used forward selection to include features in the model based on statistical significance. Moreover, we used 10-fold cross-validation to ensure that the model was not overfitted and that the results were transferrable to a similar cohort in the clinic. Predictor candidates used for inclusion are listed in Table 1 .
Herein we present and compare two examples of the classification model: (i) Model A, a 0-month model that uses baseline information; and (ii) Model B, a 3-month model that uses baseline information as well as Unless indicated otherwise, data are given as the mean ± SD or as mean values with 95% prediction intervals (PI) in parentheses. The significance of differences between the two groups were tested depending on data type and normality: proportions were tested using the Chi-squared test, normally distributed data were tested using a two-sample t-test, and non-normally distributed data were tested using the Mann-Whitney U-test. GFR, glomerular filtration rate; BMI, body mass index; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; VLDL-C, very low-density lipoprotein cholesterol.
information about weight and insulin dose changes during the first 3 months of the trial.
Classical statistical analysis
Patient characteristics and results are presented as unadjusted mean ± SD or as median values with the interquartile range (IQR) in parentheses, as appropriate. For the purpose of testing for baseline differences between group characteristics, a two-way t-test was used for normally distributed data. A Chi-squared test was used for proportions and, in particular, to test for differences in type of insulin regimen and insulin with and without metformin treatment between groups.
Results
In all, 412 participants were included in the present analysis. The median weight gain among all participants over the 18 months was 2.4 kg (95% prediction interval [PI] -5.6, 12.4 kg). Excessive weight gain, defined as the upper 4th quartile, was noted in 103 participants. The weight gain range in the 4th quartile was 6.2-22 kg with a median of 8.9 kg (95% PI 6.3, 15.2). The distribution of weight change in the study cohort is shown in Fig. 1a , whereas Fig. 1b shows time dependent changes in weight in the small and excessive weight gain groups. It is of note that the maximal weight gain for those in the excessive weight gain group is not reached within the first months of treatment. The characteristics for the small and excessive weight gain groups are given in Table 1 . At baseline, those with excessive weight gain were, on average, younger with a shorter duration of diabetes and had body weight than those with small weight gain. In addition, there was a significantly lower proportion of participants with prior insulin usage, but more participants with prior metformin use, in the group with excessive weight gain.
There were no differences in the proportion of individuals with small or excessive weight gain when the three insulin groups were analyzed separately. However, fewer subjects in the excessive weight gain group received metformin + insulin during the trial (P < 0.001). This information was not included in the final models because it did not yield any additional and independent information.
Baseline models performance
The receiver operating characteristic (ROC) curve for the baseline model is shown in Fig. 2 . Significant predictors in the baseline model for the risk of excessive weight gain are: younger age, shorter duration of diabetes, higher glomerular filtration rate (GFR), smoking, lower alcohol consumption, and less prior insulin usage. The area under the ROC curve (AUC) for the model was 0.68 ± 0.06.
Performance of the 3-month model
The ROC curve for the 3-month model is shown in Fig. 2 . Significant predictors are GFR, 3 months of weight gain, and daily insulin dose per kg bodyweight. The weight gained during the first 3 months is the strongest predictor. Substantial improvements are seen from the baseline model to the 3-month model (AUC 0.80 ±0.3) by inclusion of weight gain and insulin during the initial 3-month follow-up. Therefore, the focus will be on reporting Model B in detail. The 3-month Model B is presented in Table 2 .
For example, a cut-off with high specificity from the 3-month model could be used to predict participants with excessive weight gain. Given a sensitivity of 50% and a corresponding specificity of 89%, in a cohort of 1000 people with diabetes with insulin treatment similar to our patients, 250 people would gain excessive weight If, instead, we choose a cut-off with a high sensitivity of 90%, the corresponding specificity would be 48%. If the same 1000 people with diabetes were screened, the model would find 225 of those who would gain excessive weight and 390 false positives. This screening scenario is listed in Table 3 .
Discussion
The present study highlights the clinical factors for prediction of weight gain in a cohort of individuals with T2DM treated with insulin. Simple clinical variables may provide a clinically useful method for the prediction of those who will gain excessive weight in this population. The present cohort had a weight change of 2.4 kg (95% PI -5.6, 12.4) during the 18-months treatment period. This observed mean weight change is similar to what has been reported from the UKPDS, where the mean weight change was approximately 2.6 kg over the course of 18 months. 5 The change in weight gain the first 3 months was the strongest contributing factor to predicting 18-month weight gain. This finding may not be surprising because this measure provides direct feedback from the patient's weight response to the treatment. Although one-third of the weight gain occurred in the first 3 months, it would not be preventable. It is of note that the weight gains for those who gained excessive weight did not occur within the first months of treatment.
Using the 3-month information is reasonable at preventing overall weight gain during the follow-up period because the prediction accuracy is much higher compared with using only baseline information for prediction.
We found in the present cohort that the group with the largest weight gain during the 18-month follow-up was associated with a lower percentage of prior insulin use. This finding is in line with established knowledge that the initial treatment with insulin is related to the largest weight gain during this treatment; 10 in our study, the Figure 2 Receiver operating characteristic (ROC) curves for Model A, using only baseline information, and Model B using both baseline and 3-month follow-up data to predict excessive weight gain. group with excessive weight gain was also younger, had a shorter duration of diabetes and had fewer symptoms of peripheral neuropathy. These factors are connected to and in line with the lower percentage of prior insulin use. Balkau et al. 22 investigated factors associated with weight gain in people with T2DM starting insulin treatment and found that the main factors associated with weight gain were higher insulin dose, higher baseline HbA1c, and lower baseline body mass index (BMI). In the present study, we did not find an association between weight gain and BMI or HbA1c. Nevertheless, initial weight was significantly different between the groups. Regarding HbA1c, our cohort had lower initial levels than the group in the study of Balkau et al., 22 which could explain why HbA1c was not a significant predictor in the present study. Pontiroli et al. 23 also investigated factors associated with insulin related weight gain. They did not find baseline HbA1c as a predictor for weight gain and found that high insulin dose was associated with weight gain, which is in line with the findings of the present study: daily insulin dose (IU/day per kg) at 3 months was a highly significant (P < 0.001) predictor of weight gain. The amount of insulin prescribed was increased during the first visit (3 months from baseline), possibly as a precaution when starting insulin treatment. This may be the reason why the baseline insulin prescribed was not a good predictor of weight gain. The insulin given to each participant was continuously evaluated, but the 3-month doses were closely related to the average dose during the trial. This explains why the baseline insulin dosage was not a good predictor of weight gain in the present study.
Metformin use during insulin treatment has been reported to reduce weight gain, 24, 25 possibly because of the lower insulin dosage needed to maintain low blood glucose. 25 In the present study, the proportion of subjects on metformin + insulin treatment was lower in the group exhibiting excessive weight gain. However, this information did not provide any independent predictive information; instead, information of insulin dosage was included in the model. Glomerular filtration rate was included in the model. This predictor did provide significant independent information but the effect of this predictor was very small (see Table 2 ). It may be more practical if this predictor was removed from the model; however, it does provide independent information and could easily be set to an average estimated value when this information is not available in the clinic.
One limitation of our proposed model is that it would yield a significant proportion of false-positive predictions, depending on the chosen levels of sensitivity and specificity. However, this may not be a major problem because interventions often consist of lifestyle modifications, which have few adverse effects and would benefit false-positive cases. 7 The number of false positives must be expected when trying to separate a group based on an arbitrary threshold such as the upper 4th quartile. Future studies need to validate the model in other populations and demonstrate the effects of the model when used in the clinical setting, as well as whether the proposed prediction model eventually leads to better patient outcomes. 26, 27 In summary, we have demonstrated that the risk of excessive weight gain during insulin treatment may be predicted by using an algorithm that incorporates routine clinical variables and changes in weight and insulin dosage during the first 3 months. These findings extend previous work performed in this field by developing an operable and simple model.
Given that a substantial proportion of weight gain occurs in the first 3 months after initiating insulin therapy, a pragmatic approach would be to monitor weight on a monthly basis and, in patients gaining >1 kg, to start intervention in order to avoid further weight gain. In future work, the implications of implementing such model should be investigated.
